Mass Spec Roundup: Fragment Ions and Fossil Fragments

This week’s stories span AI-assisted metabolite annotation, spatial drug-target engagement, Denisovan proteomics, and machine-learning elemental detection.

September 16, 2026
7 min

The Analytical Scientist

Background

Mass spectrometry (MS) plays a crucial role in metabolomics, enabling the identification of metabolites that are often not represented in existing libraries. The development of AI Molecule Explorer (AIMe) expands the searchable chemical space to over 100 million small organic molecules. Additionally, advancements in imaging techniques allow for direct measurement of drug interactions in biological tissues.

Data Highlights

No numerical data available in the provided source material.

Key Findings

AIMe expands the searchable chemical space to over 100 million small organic molecules.
DeepMS2Reasoner outperformed other spectrum-prediction models with an average cosine similarity of 0.83 on the NIST dataset.
AIMe provided putative annotations for approximately 2.69 million of 7.1 million GNPS spectral clusters.
The MALDI FT-ICR imaging method achieved an average target engagement of 78 percent for the covalent drug S-XL6 in mouse brain sections.
This imaging method distinguishes between drug-bound and unmodified proteins, enhancing the understanding of drug-target interactions.

Clinical Implications

The AIMe framework may enhance the identification of metabolites in clinical settings, particularly for conditions where traditional libraries are insufficient. The imaging technique could provide valuable insights into drug efficacy and engagement in therapeutic tissues.

Conclusion

The advancements in mass spectrometry reported here highlight significant progress in metabolomics and drug development, with potential implications for clinical applications.